Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder

PHILADELPHIA, October 29, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced results from a Phase 2 signal
finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in
patients who have had residual symptoms of depression following treatment
with LEXAPRO(R) (escitlopram) for Major Depressive Disorder (MDD). Based on
these findings, Shire intends to advance …. Source article  : Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder.

Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging

DUBLIN, October 29, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty
biopharmaceutical company, announces results for the three months to
September 30, 2010.

Financial Highlights … Read the original article on Gaea Times at : Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging.